Recce Pharmaceuticals Advances Diabetic Foot Infection Trial to Pivotal Phase 3
· smallcaps.com.au
Recce Pharmaceuticals expands diabetic foot infection trial to Phase 3, broadening recruitment and adding below-knee ulcers; dual Australia-Indonesia program.
Recce Pharmaceuticals (ASX: RCE) has received Human Research Ethics Committee approval to expand and advance its Australian trial of RECCE 327 topical gel to a ...